The US-based pharmaceutical firm plans to file preliminary mid-stage results with the U.S. Food and Drug Administration (FDA), Reuters reported.
The drug is also the only DNA-based vaccine that is stable at room temperature for more than a year, at 37 degrees for over a month and has a five-year shelf life.
“Our Phase two results validate our initial Covid-19 Phase one results in a larger population, which show that INO-4800 continues to be generally safe, well-tolerated and immunogenic in all studied age groups,” Inovio’s chief scientific officer, Dr Laurent M. Humeau said.
Phase one of the study showed the vaccine was well tolerated and induced high levels of antibody responses in roughly 95 per cent of study participants.
Read more: Vaccine patents: When does free for all become a free-for-all?
The post Inovio confirms its Covid vaccine is safe in mid-stage trials appeared first on CityAM.